A literature review of the current knowledge of the disease including related clinical phenotypes, treatment approaches, update of pathogenic variants, as well as in vitro and in vivo functional models that provide pathogenic evidence and propose mechanisms fo
Thiamine
Nutrient status markers is closer to a research marker, so it should be read separately from a directly felt benefit.
Representative tier calculated from paper evidence that passed the collection audit.
Main benefit evidence
The representative ingredient tier is calculated from these target-level evidence groups.
Nutrient status3 studiesTier-BNutrient status markersFairly consistent positive signal in studiesResearch marker focusPatient-group studyThis card is closer to a measured biomarker or lab outcome than a directly felt user benefit.Closer to a research marker than a directly felt benefit.Open metrics>
Blood lipids2 studiesTier-CCholesterol and triglyceridesFairly consistent positive signal in studiesFelt benefit focusPatient-group studyPotential benefit studied in Blood lipids.Open metrics>
Glucose and metabolic health3 studiesTier-CGlucose and metabolic health markersSome positive signal observedResearch marker focusPatient-group studyThis card is closer to a measured biomarker or lab outcome than a directly felt user benefit.Closer to a research marker than a directly felt benefit.Open metrics>
Animal or cell research3 studiesTier-CAnimal or Cell-Study ClueSome positive signal observedResearch marker focusSupplement contextThis is an early research clue, not direct human supplement-effect evidence.Closer to a research marker than a directly felt benefit.Animal or cell-study clue — not a human effect probability.Open metrics>
Condition-specific evidence1 studiesTier-CCondition-specific health context in a specific contextSignal is still limitedResearch marker focusSupplement contextThis result was studied for Condition-specific health context in a narrower population or condition-specific context. It should not be generalized as an everyday supplement effect.Closer to a research marker than a directly felt benefit.Open metrics>
Research clues (read separately)
Disease-specific, biomarker, animal, or cell-study findings — not everyday felt benefits.
Specialized clinical context2 studiesTier-CSpecialized Treatment-Setting SignalSome positive signal observedDisease markerSpecialized treatmentThis evidence comes from contexts such as cancer, mortality, hospitalization, drug combination, or radiation studies. It should not be read as a general supplement effect.Closer to a research marker than a directly felt benefit.Open metrics>
Recent research
10 new papers were added in this period. No new risk signal was identified.
What's new
Most notable recent finding
Study dosage range (reference only)
Key cautions to review
Standalone side-effect signals and combination cautions are listed separately.
Side-effect and combination signals
No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.
Evidence summaries
Paper IDs and full lists are private. Only study types and summaries are shown.
This study demonstrates that high blood levels ofThiamine can be achieved rapidly with oral thiamine hydrochloride, and is absorbed by both an active and nonsaturable passive process.
It could be concluded that although experimental studies mostly resulted in beneficial effects, clinical studies of appropriate size and duration focusing on the effect of thiamine supplementation/therapy on hard endpoints are missing at present.
3 more summariesLimited representative sample by study type.>
There is not enough evidence to recommend this therapy in other types of pain due to the scarcity of high-quality studies, but combination therapy of diclofenac with TPC might have an analgesic superiority compared withdicl ofenac monotherapy in acute LBP.
Daily supplementation with an individualized ALA, carnosine, and thiamine supplement effectively reduced glucose concentration in type 2 diabetic patients, probably by increasing insulin production from the pancreas.
This real‐world study found that having a clinically unwell target population with high comorbidity and multiple presentations, coupled with challenges in cross‐cultural assessment is likely to complicate RCT findings and support a recommendation for patient‐s